Meet with us at the mRNA Based Therapeutics Summit 2022!
Boston, MA
July 26-28, 2022
Schedule a meeting with us at this year's mRNA-Based Therapeutics Summit and discover how BIOVECTRA can help with your RNA manufacturing needs.
BIOVECTRA's state-of-the-art Biomanufacturing and Vaccine Center has the:
- Capability to develop and manufacture plasmid DNA, nucleic acids, recombinant proteins, and other therapeutics expressed via microbial fermentation
- Ability to produce up to 160 million doses of mRNA vaccines per year
- Capacity to prepare and package 70 million fill/finish doses per year for commercial distribution.
BIOVECTRA specializes in clinical-to-commercial scale production capabilities for biologics, synthetic small molecules, HPAPIs, bioreagents, and pDNA/mRNA manufacturing.
Schedule a meeting with us and discover how we can support your projects and solve your most complex challenges.
With over 50 years of experience, we are a forward-thinking, North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.
© Copyright BIOVECTRA 2022.
All Rights Reserved.